A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä
Lifetime Treatment Trajectories of Mantle Cell Lymphoma: Simulation Based Analysis of 20 Years of Real‐World Data
Tekijät: Harmanen, Minna; Hujo, Mika; Sund, Reijo; Sorigue, Marc; Khan, Madiha; Prusila, Roosa; Klaavuniemi, Tuula; Kari, Esa; Jantunen, Esa; Sunela, Kaisa; Rajamäki, Aino; Alanne, Erika; Kuitunen, Hanne; Sancho, Juan‐Manuel; Jukkola, Arja; Rönkä, Aino; Kuittinen, Outi.
Kustantaja: Wiley
Julkaisuvuosi: 2025
Journal: Hematological Oncology
Tietokannassa oleva lehden nimi: Hematological Oncology
Artikkelin numero: e70024
Vuosikerta: 43
Numero: 1
ISSN: 0278-0232
eISSN: 1099-1069
DOI: https://doi.org/10.1002/hon.70024
Verkko-osoite: https://doi.org/10.1002/hon.70024
Mantle cell lymphoma is a rare type of B-cell lymphoma, which is considered incurable yet treatable. In recent years, the treatment options of mantle cell lymphoma have multiplied, and the focus of treatment is expected to shift from traditional chemoimmunotherapy toward precision medicine. However, this development is hindered by the high costs of targeted therapies. To provide a baseline for future assessment of costs and benefits of new and emerging MCL treatments, we established a predictive simulated model of lifetime treatment trajectories based on a retrospective cohort of chemoimmunotherapy era patients diagnosed and treated between the year 2000 and 2020.
Julkaisussa olevat rahoitustiedot:
Minna Harmanen has received financial support from following organizations: Finnish Cancer Foundation (personal research grant); North Savonian Cancer Association (personal research grant); and Northern Finland Healthcare Support Foundation (personal working grant).
Aino Rönkä and Outi Kuittinen collaborated for this work at equal contribution.
